BackgroundThe dramatic increase in exposure to non-native sources of electromagnetic fields (EMF) in recent years has given rise to numerous human health concerns. The near pervasive exposure to radiofrequency (RF) emanating from wireless technologies inside the home (e.g., cell phones, wireless routers, "Smart" devices) and outside of the home (e.g., cell towers, automobiles, computers at work, tablets at school) is particularly troubling. While epidemiological studies are somewhat conflicting to date, RF exposure is currently classified by the World Health Organization as a Class 2B carcinogen. Mechanisms of activity of the deleterious effects of RF exposure on human health include the generation of excessive oxidative stress, chronic inflammation, and disruption of the production of melatonin and other hormones, all of which are believed to be due largely to the activation of voltage-gated calcium channels (VGCC). Mitigation strategies are currently generally limited to wireless device hygiene (e.g., hard-wired ethernet, turning off wireless routers at night, keeping cellphones away from the body) and metal-based shielding in the home, which can be expensive and not feasible for many. The goal of this pilot and feasibility trial was to evaluate the feasibility and preliminary signs of efficacy of an in-home resonance-based electromagnetic field protection device (BluShield) on various physiological and patient-reported outcomes commonly affected by excessive RF exposure.MethodsA sample of relatively healthy adults was enrolled in a single arm, 12-week pilot and feasibility study. The intervention consisted of plugging in the BluShield device at home or at the participant's residence when traveling. Outcomes included laboratory panels assessing overall physiological health (CBC & CMP), blood markers related to inflammation, oxidative stress, DNA damage, and cellular senescence (Jinfiniti), a high-resolution genome-wide assessment of DNA methylation (TruDiagnostic), a validated questionnaire to assess cognitive function (CNS - Vital Signs), a wearable device to assess sleep and other physiological parameters (Oura ring), and a single-item assessment of overall health. Outcomes were compared before and after the intervention with paired t tests or Wilcoxon signed rank tests, depending upon the distribution of data.Results25 participants enrolled in the study. All participants reported compliance with the EMF mitigation device throughout the course of the study, and no adverse events were reported. There were limited changes in conventional labs (decrease in glucose, increase in monocytes; P < .04]), but modest improvement in self-reported health (P = .02), improvements on numerous domains of the CNS - Vital Signs questionnaire (Composite Memory, Cognitive Flexibility, Executive Function, and Processing Speed; P < .02), wearable device parameters (deep sleep, heart rate variability, resting heart rate, and body temperature; P < .04), and perhaps most interestingly, hypermethylation of genes involved in RF exposure (including a key VGCC gene [CACNA1G]; P = .000045).DiscussionThe use of the BluShield is feasible and revealed improvements in some markers of sleep, cognitive function, and overall health. These improvements may be due in part to suppression of VGCC activity, which previous literature has demonstrated is activated by RF exposure and can generate oxidative stress and inflammation. An RF mitigation strategy should focus primarily on limiting modifiable exposures within the home, and the device appears to be a promising component of a comprehensive approach.. Controlled studies are needed to mitigate potential sources of confounding in this single-arm pilot study. A specific focus among populations with excessive RF exposures that are not modifiable within the home, such as those living in high-density urban settings, in close proximity to cell towers, or certain occupational hazards, also appears warranted.